These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 33917020)

  • 1. Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System.
    Raschi E; Fusaroli M; Ardizzoni A; Poluzzi E; De Ponti F
    Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33917020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment.
    Raschi E; Fusaroli M; Ardizzoni A; Poluzzi E; De Ponti F
    Breast Cancer Res Treat; 2021 Feb; 186(1):219-227. PubMed ID: 33150548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Skin Toxicities with Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Signals from Disproportionality Analysis of the FDA Adverse Event Reporting System.
    Raschi E; Fusaroli M; La Placa M; Ardizzoni A; Zamagni C; Poluzzi E; De Ponti F
    Am J Clin Dermatol; 2022 Mar; 23(2):247-255. PubMed ID: 34699032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between cyclin-dependent kinase 4/6 inhibitors and venous thromboembolism: analysis of F.A.E.R.S. data.
    Yan MM; Wu SS; Qi YP; Li ZR; Zhang Q; Zhao H; Zhong MK; Qiu XY
    Expert Opin Drug Saf; 2022 Feb; 21(2):277-283. PubMed ID: 34581647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thromboembolism profiles associated with cyclin-dependent kinase 4/6 inhibitors: a real-world pharmacovigilance study and a systematic review.
    Gao S; Li Y; He Z; Zhu J; Liang D; Yang S; Mo J; Lam K; Yu X; Huang M; Wu J
    Expert Opin Drug Saf; 2023; 22(7):599-609. PubMed ID: 36794339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spectrum of psychiatric adverse reactions to cyclin-dependent kinases 4/6 inhibitors: A pharmacovigilance analysis of the FDA adverse event reporting system.
    Xiao Z; Cao J; Wu S; Zhou T; Li C; Duan J; Yang Z; Xu F
    CNS Neurosci Ther; 2024 Jul; 30(7):e14862. PubMed ID: 39009505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Haematopoietic cytopenia associated with cyclin-dependent kinase 4/6 inhibitors: A real-world study of data from the food and drug administration adverse event reporting system database.
    Ren X; Yan C; Tian L; Cui X
    Int J Immunopathol Pharmacol; 2022; 36():3946320221145520. PubMed ID: 36565299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infection associated with CDK4/6 inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system database.
    Chen J; Tang L; Song W; Sun C; Zhang W
    Front Pharmacol; 2024; 15():1371346. PubMed ID: 39011505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thromboembolic events associated with immune checkpoint inhibitors: A real-world study of data from the food and drug administration adverse event reporting system (FAERS) database.
    Li H; Sun X; Sun D; Zhao J; Xu Z; Zhao P; Ma Z; Zhang Y
    Int Immunopharmacol; 2021 Sep; 98():107818. PubMed ID: 34130149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A disproportionality analysis of CDK4/6 inhibitors in the FDA Adverse Event Reporting System (FAERS).
    Peng Y; Zhou Y; Zhou X; Jia X; Zhong Y
    Expert Opin Drug Saf; 2024 Aug; ():1-9. PubMed ID: 39083396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disproportionality Analysis of Abemaciclib in the FDA Adverse Event Reporting System: A Real-World Post-Marketing Pharmacovigilance Assessment.
    Shu Y; Wang L; Ding Y; Zhang Q
    Drug Saf; 2023 Sep; 46(9):881-895. PubMed ID: 37418089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors.
    Verden A; Dimbil M; Kyle R; Overstreet B; Hoffman KB
    Drug Saf; 2018 Apr; 41(4):357-361. PubMed ID: 29196988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data.
    Mease P; Charles-Schoeman C; Cohen S; Fallon L; Woolcott J; Yun H; Kremer J; Greenberg J; Malley W; Onofrei A; Kanik KS; Graham D; Wang C; Connell C; Valdez H; Hauben M; Hung E; Madsen A; Jones TV; Curtis JR
    Ann Rheum Dis; 2020 Nov; 79(11):1400-1413. PubMed ID: 32759265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thromboembolic events in Janus kinase inhibitors: A pharmacovigilance study from 2012 to 2021 based on the Food and Drug Administration's Adverse Event Reporting System.
    Dong Z; Ye X; Chen C; Wang R; Liu D; Xu X; Zhou X; He J
    Br J Clin Pharmacol; 2022 Sep; 88(9):4180-4190. PubMed ID: 35466415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CDK4/6 inhibitors in drug-induced liver injury: a pharmacovigilance study of the FAERS database and analysis of the drug-gene interaction network.
    She Y; Guo Z; Zhai Q; Liu J; Du Q; Zhang Z
    Front Pharmacol; 2024; 15():1378090. PubMed ID: 38633610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System.
    Raschi E; Mazzarella A; Antonazzo IC; Bendinelli N; Forcesi E; Tuccori M; Moretti U; Poluzzi E; De Ponti F
    Target Oncol; 2019 Apr; 14(2):205-221. PubMed ID: 30927173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems.
    Raschi E; Parisotto M; Forcesi E; La Placa M; Marchesini G; De Ponti F; Poluzzi E
    Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1098-1107. PubMed ID: 29174026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of thrombopoietin-related drugs with thromboembolic events: Mendelian randomization and a real-world study.
    Liang C; Chen Q; Zhang Y
    Ther Adv Drug Saf; 2024; 15():20420986231224236. PubMed ID: 38293563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib.
    Peng L; Xiao K; Ottaviani S; Stebbing J; Wang YJ
    Expert Opin Drug Saf; 2020 Nov; 19(11):1505-1511. PubMed ID: 32693646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hematological toxicity of cyclin-dependent kinase 4/6 inhibitors in patients with breast cancer: a network meta-analysis and pharmacovigilance study.
    Ding H; Xu W; Dai M; Li S; Xin W; Tong Y; He C; Mi X; Zhan Z; Fang L
    Expert Opin Drug Saf; 2024 May; ():1-9. PubMed ID: 38753541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.